Gateway 2011:Dwyer Instruments Inc - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011:Dwyer Instruments Inc



Your online Gateway to Dwyer Instruments Inc. in 2011

P. O. Box 373
Michigan City, IN 46361
1-800-872-9141
Fax: 219-872-9057
www.dwyer-inst.com

About Dwyer Instruments Inc.

Dwyer Instruments Inc., founded in 1931, manufactures a broad range of competitively priced, quality precision instruments for measuring, transmitting, and controlling pressure, temperature, level, and flow.  Many of these instruments are widely known by their individual brand names, such as Magnehelic® and Spirahelic® pressure gages, Photohelic® switch/gages, Rate-Master®, Mini-Master® and Visi-Float® Flowmeters, Slack-Tube® and Flex-Tube® manometers, and Dwyer® pressure switches.

Other established Dwyer brands, including Flotect® flow and level switches, Hi-Flow® valves, Self-tune® temperature controllers and Iso-Verter® signal converter/isolators, are the products of companies that are now divisions of Dwyer Instruments – Mercoid, W. E. Anderson, Proximity Controls and Love Controls.

Visit our Booth: # 2937

We will be featuring many of our new products which include the Mercoid® Series 3100 Smart Pressure Transmitter.  A microprocessor-based high performance transmitter, which has flexible pressure calibration, push button configuration, and programmable using HART® Communication. The Series 3100 is capable of being configured for differential pressure or level applications with the zero and span buttons. A field calibrator is not required for configuration. The transmitter software compensates for thermal effects, improving performance. EEPROM stores configuration settings and stores sensor correction coefficients in the event of shutdowns or power loss. The Series 3100 is FM approved for use in hazardous (classified) locations. The 100:1 rangeability allows the smart transmitter to be configured to fit any application.

 

For more information:

info@dwyer-inst.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here